New therapeutic options in systemic treatment of advanced cutaneous melanoma

Expert Opinion on Investigational Drugs

Volumn 22, Issue 2, 2013, Pages 181-190

  Mackiewicz Wysocka, Malgorzata ^a   Zolnierek, Jakub ^b   Wysocki, Piotr J ^a,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

^c GREATER POLAND CANCER CENTER   (Poland)

Author keywords

BRAF mutations; Dabrafenib; Immunotherapy; Ipilimumab; Melanoma; PD1; Trametinib; Vemurafenib

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; BMS 936553; BMS 936559; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; GLYCOPROTEIN GP 100; IMMUNOMODULATING AGENT; IPILIMUMAB; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

ARTHRALGIA; CANCER CHEMOTHERAPY; CUTANEOUS MELANOMA; DENDRITIC CELL; DIABETES MELLITUS; DRUG EFFICACY; ENDOPHTHALMITIS; FATIGUE; HEPATITIS; HUMAN; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; PROTEIN PROTEIN INTERACTION; RASH; REVIEW; SARCOIDOSIS; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; CYTOKINES; ENZYME INHIBITORS; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84872191246     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.748032     Document Type: Review

References (54)

1. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-206
2. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010;21(SUPPL7):vii339-44
3. Eggermont AM, Schadendorf D. Melanoma and immunotherapy. Hematol Oncol Clin North Am 2009;23:547-64; ix-
4. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-Tumor immunity. Immunol Rev 2009;229:126-44
5. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 2006;29:233-40 (Pubitemid 44297291)
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-Dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16 (Pubitemid 29318842)
7. Hamm C, Verma S, Petrella T, et al. Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review. Cancer Treat Rev 2008;34:145-56
8. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
9. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-pD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23 . Results of a Phase III study with ipilimumab as second-line treatment
11. Mackiewicz A, Mackiewicz J, Wysocki PJ, et al. Long-Term survival of high-Risk melanoma patients immunized with a Hyper-IL-6-Modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs 2012;21:773-83
12. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
13. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-pD-1 antibody in cancer. N Engl J Med 2012;366:2443-54
14. Petrella TM, Tozer R, Belanger K, et al. Interleukin-21 has activity in patients with metastatic melanoma: A phase II study. J Clin Oncol 2012;30:3396-401
15. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106 (Pubitemid 46160986)
16. Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials. Cancer Immun 2010;10:9
17. Hersh EM, O'Day SJ, Powderly J, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 2011;29:489-98
18. Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81
19. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008;26:abstract LBA9011
20. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: An update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739-45 (Pubitemid 46348742)
21. Jin HT, Ahmed R, Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011;350:17-37
22. Li B, VanRoey M, Wang C, et al. Anti-programmed death-1 synergizes with granulocyte macrophage colony-Stimulating factor-Secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res 2009;15:1623-34
23. Wang W, Lau R, Yu D, et al. PD1 blockade reverses the suppression of melanoma antigen-Specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol 2009;21:1065-77
24. Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol 2010;184:3442-9
25. Swick JM, Maize JCS. Molecular biology of melanoma. J Am Acad Dermatol 2012;67(5):1049-54
26. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 2006;16:97-103 (Pubitemid 44090041)
27. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6 (Pubitemid 46630793)
28. Schoenewolf NL, Bull C, Belloni B, et al. Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. Eur J Cancer 2012;48:1842-52
29. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47 (Pubitemid 41653105)
30. Eisen T, Marais R, Affolter A, et al. Sorafenib and dacarbazine as first-line therapy for advanced melanoma: Phase I and open-label phase II studies. Br J Cancer 2011;105:353-9
31. Ott PA, Hamilton A, Min C, et al. A phase II trial of sorafenib in metastatic melanoma with tissue correlates. PLoS One 2010;5:e15588
32. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
33. Mangana J, Levesque MP, Karpova MB, Dummer R. Sorafenib in melanoma. Expert Opin Investig Drugs 2012;21:557-68
34. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
35. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-Mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
36. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
37. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-Mutated melanoma. J Clin Oncol 2012;30:abstract 8502
38. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366:207-15
39. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012;30:2375-83
40. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012;366(5):480-1
41. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-Mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
42. Kirkwood JM, Long GV, Trefzer U, et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/K mutation-positive melanoma with brain metastases. J Clin Oncol 2012;30:abstract 8501
43. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7
44. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29:3085-96
45. Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90
46. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18:683-95
47. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-Mutated melanoma. N Engl J Med 2012;367:107-14
48. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012; 367: 1694-703
49. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-Related response criteria. Clin Cancer Res 2009;15:7412-20
50. Rubin KM. Managing immune-Related adverse events to ipilimumab: A nurse's guide. Clin J Oncol Nurs 2012;16:E69-75
51. Weber JS, Kahler KC, Hauschild A. Management of immune-Related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-7
52. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34
53. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-Arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9
54. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012;366:925-31